Abstract Number: 2456 • 2017 ACR/ARHP Annual Meeting
Disease Flares Among Early Rheumatoid Arthritis Patients Treated with Continued Methotrexate Either Alone or in Combination with Adalimumab (Humira)
Background/Purpose : Some rheumatoid arthritis (RA) patients (pts) may experience flares in their disease even after reaching stable low disease activity (sLDA), but the consequences…Abstract Number: 2457 • 2017 ACR/ARHP Annual Meeting
Sarilumab for the Treatment of Active, Moderate-to-Severe Rheumatoid Arthritis (RA): An Analysis of Cost per Effectively Treated Patient
Background/Purpose: The MONARCH study (NCT02332590) evaluated monotherapy with sarilumab 200 mg subcutaneous (SC) + placebo every 2 weeks (Q2W) versus adalimumab 40 mg SC +…Abstract Number: 2458 • 2017 ACR/ARHP Annual Meeting
Tocilizumab Inhibits Progression of Erosive Joint Damage in Early Rheumatoid Arthritis More Effectively Than Step-up Methotrexate Therapy
Background/Purpose: In early rheumatoid arthritis (RA), starting therapy as soon as possible is important to reduce disease activity and preserve the joints. With application of…Abstract Number: 2459 • 2017 ACR/ARHP Annual Meeting
Incidence of Disease Worsening in Inflammatory Arthritis Patients on Long-Term Infliximab (Remicade®) Therapy
Background/Purpose: A recent randomized controlled study in a single country reported rates of disease worsening over a one-year follow-up period for innovator infliximab (IFX) and…Abstract Number: 2460 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Background/Purpose: Patients with rheumatoid arthritis (RA) often receive methotrexate (MTX) in combination with biologics; however, MTX may be discontinued due to intolerance or to reduce…Abstract Number: 2461 • 2017 ACR/ARHP Annual Meeting
Rituximab Is Effective in the Treatment of Rheumatoid Arthritis Irrespective of Body Mass Index; Up to 48 Weeks Results from Phase 3 Study
Background/Purpose: High body mass index (BMI) is known to be associated with inadequate clinical response to anti-TNF agents in RA patients.1 However, there are limited…Abstract Number: 2462 • 2017 ACR/ARHP Annual Meeting
Tapering TNF Inhibitors in Rheumatoid Arthritis: A Retrospective Study
Background/Purpose: Current guidelines on RA treatment recommend tapering of biologic DMARDs for patients in persistent remission. Methods: In this retrospective study we used the hospital…Abstract Number: 2463 • 2017 ACR/ARHP Annual Meeting
Golimumab in Biologic-NaïVe Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis from a Non-Interventional Evaluation in Germany
Background/Purpose: Golimumab (GLM) has demonstrated efficacy and safety in several randomized clinical trials with biologic-naïve patients (pts.). However, more data regarding the effectiveness and patient-reported…Abstract Number: 2464 • 2017 ACR/ARHP Annual Meeting
Similar Effectiveness of Both Formulations of Tocilizumab (TCZ) in Patients with Rheumatoid Arthritis (RA) Switching from Intravenous (IV) to Subcutaneous (SC) at 6 Months in Real Life
Background/Purpose: It has been proven, in a pivotal RCT, that SC TCZ was non-inferior to IV TCZ [1]. However, the effectiveness of the SC TCZ…Abstract Number: 2465 • 2017 ACR/ARHP Annual Meeting
Association between Methotrexate Use and Effects of Treatment with a Second Biologic Agent in Rheumatoid Arthritis: A Multiple Imputation Approach
Background/Purpose: Methotrexate (MTX) is recommended and widely prescribed as the first-line, evidence-based therapy for rheumatoid arthritis (RA) patients. Previous studies have demonstrated a significant effect…Abstract Number: 2466 • 2017 ACR/ARHP Annual Meeting
Radiographic Progression By Disease Activity States in Patients with Rheumatoid Arthritis Treated with SB2 or Reference Infliximab
Background/Purpose: Based on the totality of evidence, SB2 has shown to be similar with reference infliximab (INF) and has been approved as a biosimilar by…Abstract Number: 2467 • 2017 ACR/ARHP Annual Meeting
Evaluation of Radiographic Progression By Disease Activity States in Patients with Rheumatoid Arthritis Treated with SB4 or Reference Etanercept: Results from a Phase III Study
Background/Purpose : SB4 has been approved as a biosimilar of the reference etanercept by the European Commission. Results including one year radiographic progression from the…Abstract Number: 2468 • 2017 ACR/ARHP Annual Meeting
Efficacy of Sarilumab in Patients with Rheumatoid Arthritis Who Previously Received Sarilumab or Tocilizumab
Background/Purpose: ASCERTAIN (NCT01768572) was a 24-week, randomized, double-blind, double-dummy, parallel-group, 3-arm, safety study in patients with RA and inadequate response to or intolerance of TNF…Abstract Number: 2469 • 2017 ACR/ARHP Annual Meeting
Median Time to Lda Is Shorter in Tocilizumab Combination Therapy with Csdmards As Compared to Monotherapy in Patients with Active Rheumatoid Arthritis and Inadequate Responses to Csdmards and/or TNF Inhibitors: Sub-Analysis of the Swiss and Austrian Patients from the ACT-SURE Study
Background/Purpose: To analyze efficacy and safety of tocilizumab in patients with rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease modifying anti-rheumatic drugs…Abstract Number: 2470 • 2017 ACR/ARHP Annual Meeting
Efficacy of Sarilumab in Combination with Csdmards in Patients with Rheumatoid Arthritis and Inadequate Response to TNF Inhibitors By Baseline Levels of Disease Activity
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. In the phase 3 TARGET study (NCT01709578), sarilumab (150 or 200 mg subcutaneously every 2 weeks…
ACR Meeting Abstracts